DPYD genotype-guided dose individualisation of fluoropyrimidine therapy: who and how? reply

2019

The Lancet Oncology , Volume 20 - Issue 2 p. E67- E67

Additional Metadata
Persistent URL	doi.org/10.1016/S1470-2045(19)30010-5, hdl.handle.net/1765/115252
Journal	The Lancet Oncology
Organisation	Department of Medical Oncology
Citation APA Style AAA Style APA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	Henricks, L.M, Lunenburg, C., Cats, A., Mathijssen, R., Guchelaar, H. J., & Schellens, J. (2019). DPYD genotype-guided dose individualisation of fluoropyrimidine therapy: who and how? reply. The Lancet Oncology, 20(2), E67–E67. doi:10.1016/S1470-2045(19)30010-5

Publication